BJH - 2025, issue Special, april 2025
T. Feys MBA, MSc
The annual Pierre Stryckmans Memorial Lecture at the 2025 edition of the BHS-GAM was presented by Prof. Dr. Giovanni Palladini from the Amyloidosis Research and Treatment Centre at the University of Pavia in Italy. With this lecture, Prof. Palladini was paid tribute for his lifelong commitment to improving the management of patients with light-chain (AL) amyloidosis.
Read moreBJH - volume 15, issue 5, september 2024
T. Feys MBA, MSc
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J HEMATOL 2024;15(5):211)
Read moreBJH - volume 15, issue 3, may 2024
T. Feys MBA, MSc
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J HEMATOL 2024;15(3):130)
Read moreBJH - 2024, issue Special, may 2024
J. Collins PhD, T. Feys MBA, MSc
Chemoimmunotherapy (CIT) has been the long-standing cornerstone of the first line treatment for patients with chronic lymphocytic leukaemia (CLL). More recently, however, continuous treatment with Bruton’s tyrosine kinase inhibitors (BTKis) emerged as a new standard of care frontline treatment for the majority of CLL patients. However, the continuous nature of this treatment modality is associated with a considerable treatment burden, long-term toxicity and potential clonal selection. Therefore, research efforts have focused on the development of new, time-limited and chemotherapy-free first line treatment regimens for patients with CLL.1 In this mini review, the main clinical trial results with these different fixed-duration regimens are summarised.
Read moreBJH - 2024, issue Special, may 2024
A. Enguita PhD, T. Feys MBA, MSc
Bruton tyrosine kinase inhibitors (BTKis) have revolutionised the treatment landscape for patients with chronic lymphocytic leukaemia (CLL) and several non-Hodgkin lymphoma (NHL) subtypes, including mantle cell lymphoma (MCL). Despite the efficacy of covalent BTKis (cBTKis), the development of resistance mutations leads to poor outcomes in patients who relapse after a cBTKi-based therapy. Non-covalent BTKis (ncBTKis), such as pirtobrutinib, have a different mode of action than cBTKis allowing them to overcome this acquired resistance. In recent years, several clinical trials have yielded promising results with pirtobrutinib and other ncBTKis in patients progressing on a cBTKi. This article zooms in on the unmet clinical needs of cBTKi-resistant patients, exploring pivotal findings from clinical trials assessing pirtobrutinib in this context, alongside other prospective strategies.
Read moreBJH - 2024, issue Special, may 2024
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In recent years, the treatment landscape of patients with relapsed or refractory diffuse-large B-cell lymphoma (R/R DLBCL) has changed dramatically. This mini review will briefly discuss the clinical trial data that were obtained with these different options.
Read moreBJH - 2024, issue Special, may 2024
J. Collins PhD, T. Feys MBA, MSc
Follicular lymphoma (FL) is the most common B-cell non-Hodgkin lymphoma (NHL) and typically follows an indolent disease course. While some patients do not require treatment until certain criteria are met, others may progress to an aggressive lymphoma phenotype requiring a different treatment approach. The current standard initial treatment for FL consists of chemo-immunotherapy in which cytotoxic chemotherapy is combined with an anti-CD20 antibody. In general, this treatment strategy is highly effective, significantly delaying disease progression and postponing the need for additional therapy for many years. However, a proportion of patients may experience chemotherapy-related toxicities, while others prove to be chemotherapy-refractory. For these patients, an effective chemotherapy-free treatment approach is sought. This article provides a concise overview of the mechanisms of action of potential targeted therapies for FL and briefly discusses the available clinical trial data.1
Read more